Skip to main content
NKTR logo

NKTR · Nektar Therapeutics · Webcasts, Transcripts & Audio

Track NKTR — free
$36.29 -0.98 (-2.63%) Play latest call Q3 2026 earnings call transcript
Market Cap
$1.28B
Shares
34.21M
Volume · Nov 16 214.15K Avg daily vol (3M) 1.1M

Nektar Therapeutics Webcasts

Earnings calls, investor updates, investor days and conferences for Nektar Therapeutics (NKTR), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Conference
Investor event
2026-11-18
Nektar Therapeutics (NKTR) November 18, 2026 Conference
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-11-17
Nektar Therapeutics (NKTR) November 17, 2026 Conference
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q3
2026-11-12
Nektar Therapeutics (NKTR) Q3 2026 Earnings Call Transcript
Confident tone RESPEG Phase III registrational progress Alopecia areata development Vitiligo expansion
Revenue
$9.39M
▼ 20.4% YoY
Diluted EPS
$-1.63
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Investor Update
Investor event
2026-10-01
Nektar Therapeutics (NKTR) October 1, 2026 Investor Update Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-13
Nektar Therapeutics (NKTR) Q2 2026 Earnings Call Transcript
Confident tone Market research and first-line positioning for ResPeg Atopic dermatitis dosing durability Alopecia areata Phase 3 / long-term extension
Revenue
$10.13M
▼ 9.3% YoY
Diluted EPS
$-1.23
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-03
Nektar Therapeutics (NKTR) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-07
Nektar Therapeutics (NKTR) Q1 2026 Earnings Call Transcript
Confident tone Atopic dermatitis (ectopic dermatitis) program Alopecia areata program Regulatory risk on moderate-population expansion
Revenue
$10.86M
▲ 3.8% YoY
Diluted EPS
$-1.82
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Investor Update
Investor event
2026-04-20
Nektar Therapeutics (NKTR) April 20, 2026 Investor Update Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-03-12
Nektar Therapeutics (NKTR) Q4 2025 Earnings Call Transcript
Confident tone Rezpeg/Respag in atopic dermatitis Rezpeg in alopecia areata Phase 3 readiness and regulatory alignment
Revenue
$21.81M*
▼ 25.3% YoY
Gross margin
100.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Nektar Therapeutics (NKTR) Q3 2025 Earnings Call Transcript
Confident tone Alopecia areata Phase IIb (RESOLVE-AA) REZPEG in atopic dermatitis (RESOLVE-AD) Phase III planning and FDA interactions
Revenue
$11.79M
▼ 51.1% YoY
Diluted EPS
$-1.87
Gross margin
100.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Nektar Therapeutics (NKTR) Q2 2025 Earnings Call Transcript
Confident tone REZPEG/rezpegaldesleukin lead program Atopic dermatitis Phase IIb REZOLVE-AD results FDA Fast Track and Phase III planning
Revenue
$11.18M
▼ 52.4% YoY
Diluted EPS
$-2.95
Gross margin
100.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Transcript
Positive tone REZPEG in atopic dermatitis (REZOLVE-AD) Early-stage pipeline (TNFR2 agonist) REZPEG in alopecia areata
Revenue
$10.46M
▼ 51.7% YoY
Diluted EPS
$-3.62
Gross margin
100.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-12
Nektar Therapeutics (NKTR) Q4 2024 Earnings Call
Revenue
$29.18M*
▲ 22.1% YoY
Gross margin
72.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Transcript
Confident tone REZPEG in atopic dermatitis REZPEG in alopecia areata NKTR-255 oncology program
Revenue
$24.12M
▼ 0.1% YoY
Diluted EPS
$-2.66
Gross margin
81.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Nektar Therapeutics (NKTR) Q2 2024 Earnings Call
Revenue
$23.49M
▲ 14.6% YoY
Diluted EPS
$-3.76
Gross margin
58.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Nektar Therapeutics (NKTR) Q1 2024 Earnings Call Transcript
Confident tone REZPEG in atopic dermatitis REZPEG in alopecia areata NKTR-0165 TNFR2 agonist
Revenue
$21.64M
▲ 0.2% YoY
Diluted EPS
$-2.85
Gross margin
60.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-04
Nektar Therapeutics (NKTR) Q4 2023 Earnings Call Transcript
Confident tone REZPEG in atopic dermatitis REZPEG in alopecia areata TNFR2 / NKTR-0165 program
Revenue
$23.89M*
▲ 8.5% YoY
Gross margin
69.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Nektar Therapeutics (NKTR) Q3 2023 Earnings Call Transcript
Revenue
$24.14M
▲ 2.2% YoY
Diluted EPS
$-3.60
Gross margin
48.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Nektar Therapeutics (NKTR) Q2 2023 Earnings Call Transcript
Revenue
$20.50M
▼ 5% YoY
Diluted EPS
$-4.05
Gross margin
65.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-04-17
Nektar Therapeutics (NKTR) Q1 2023 Earnings Call Transcript
Revenue
$21.59M
▼ 13% YoY
Diluted EPS
$-10.95
Gross margin
67.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Nektar Therapeutics (NKTR) Q4 2022 Earnings Call
Revenue
$22.02M*
▼ 11.9% YoY
Gross margin
71.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Nektar Therapeutics (NKTR) Q3 2022 Earnings Call Transcript
Revenue
$23.62M
▼ 5.2% YoY
Diluted EPS
$-4.65
Gross margin
79.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Nektar Therapeutics (NKTR) Q2 2022 Earnings Call Transcript
Revenue
$21.59M
▼ 23.8% YoY
Diluted EPS
$-12.75
Gross margin
76.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Nektar Therapeutics (NKTR) Q1 2022 Earnings Call
Revenue
$24.82M
▲ 5% YoY
Diluted EPS
$-7.35
Gross margin
78.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-01-11
Nektar Therapeutics (NKTR) Q4 2021 Earnings Call Transcript
Revenue
$25.01M
▲ 6.6% YoY
Diluted EPS
$-11850.00
Gross margin
75.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Nektar Therapeutics (NKTR) Q3 2021 Earnings Call Transcript
Revenue
$24.92M
▼ 17% YoY
Diluted EPS
$-10.50
Gross margin
78.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Nektar Therapeutics (NKTR) Q2 2021 Earnings Call Transcript
Revenue
$28.33M
▼ 42% YoY
Diluted EPS
$-10.35
Gross margin
72.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Nektar Therapeutics (NKTR) Q1 2021 Earnings Call Transcript
Revenue
$23.65M
▼ 53.2% YoY
Diluted EPS
$-10.20
Gross margin
75.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-01-11
Nektar Therapeutics (NKTR) Q4 2020 Earnings Call Transcript
Revenue
$23.46M
▼ 30.7% YoY
Diluted EPS
$-9.75
Gross margin
81.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Nektar Therapeutics (NKTR) Q3 2020 Earnings Call Transcript
Revenue
$30.03M
▲ 2.8% YoY
Diluted EPS
$-9.15
Gross margin
81.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Nektar Therapeutics (NKTR) Q2 2020 Earnings Call Transcript
Revenue
$48.85M
▲ 109.5% YoY
Diluted EPS
$-6.75
Gross margin
88.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Nektar Therapeutics (NKTR) Q1 2020 Earnings Call Transcript
Revenue
$50.57M
▲ 79.2% YoY
Diluted EPS
$-11.70
Gross margin
92.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-01-13
Nektar Therapeutics (NKTR) Q4 2019 Earnings Call
Revenue
$33.86M
▼ 15% YoY
Diluted EPS
$-9.60
Gross margin
82.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–33 of 33 webcasts
Key facts CIK 906709 CUSIP 640268306 13F (30d) 199 filings 164 filers Visit website Investor relations